159 related articles for article (PubMed ID: 36035942)
21. The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study.
Hsu JC; Nguyen PA; Chen YT; Yang SC; Lin CC; Yang YH; Lin YC; Hsia TC; Hsieh HC; Wu JS; Chang CP; Feng YH; Lin PC; Hsu PC; Tzeng HE; Chien SC; Chang WC; Chang CC; Yang HC; Lee CM; Lu CY
Front Oncol; 2021; 11():671127. PubMed ID: 34307141
[TBL] [Abstract][Full Text] [Related]
22. Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study.
Bao Z; Luo L; Xu T; Yang J; Lv M; Ni L; Sun X; Chen W; Zhou L; Wang X; Xiang Y; Gao B
Ann Transl Med; 2022 Sep; 10(18):967. PubMed ID: 36267724
[TBL] [Abstract][Full Text] [Related]
23. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
24. A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors.
Wang Z; Hu C; Zhang A; Wang X; Zeng D; Long T; Zhu B; Wang Z
Ann Transl Med; 2023 Feb; 11(4):164. PubMed ID: 36923080
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
26. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
27. Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center.
Park JH; Yoon D; Lee J; Oh SJ; Kim HJ; Lee JH; Lee DY
J Dermatol; 2021 Jul; 48(7):979-988. PubMed ID: 33878219
[TBL] [Abstract][Full Text] [Related]
28. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
29. Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study.
Tan S; Spear E; Sane N; Chan J; Nelson AJ; Alamgeer M; Nerlekar N; Segelov E; Nicholls SJ
Heart Lung Circ; 2024 May; 33(5):721-729. PubMed ID: 38042638
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
Front Oncol; 2020; 10():654. PubMed ID: 32656072
[No Abstract] [Full Text] [Related]
31. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
Zhao D; Mambetsariev I; Li H; Chen C; Fricke J; Fann P; Kulkarni P; Xing Y; Lee PP; Bild A; Massarelli E; Koczywas M; Reckamp K; Salgia R
Lung Cancer; 2020 Aug; 146():174-181. PubMed ID: 32554069
[TBL] [Abstract][Full Text] [Related]
32. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
33. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.
Cui C; Deng L; Wang W; Ren X; Wang Y; Cui W
Front Oncol; 2022; 12():941079. PubMed ID: 36059699
[TBL] [Abstract][Full Text] [Related]
34. Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Ma Z; Pei J; Sun X; Liu L; Lu W; Guo Q; Lyu J; Liu Y; Zhang Y; Zhao Z
Front Pharmacol; 2021; 12():663088. PubMed ID: 34276364
[No Abstract] [Full Text] [Related]
35. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
36. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
37. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis.
She J; Liu H; Wu H; Tuerhongjiang G; Zheng T; Bai L
Front Cardiovasc Med; 2022; 9():838488. PubMed ID: 35711379
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
